Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial

Dipen J. Parekh(University of Miami), Ian M. Thompson(The University of Texas at San Antonio Health Science Center), Vivek Venkatramani(University of Miami), Robert S. Svatek(The University of Texas at San Antonio Health Science Center), Alon Z. Weizer(University of Michigan), Edward Uchio(University of California, Irvine), Kerri Kendrick(The University of Texas at San Antonio Health Science Center), Alex Gorbonos(Loyola University Medical Center), Tracey L. Krupski(University of Virginia Cancer Center), Lynn Shemanski(Cancer Research And Biostatistics), Michael S. Cookson(University of Oklahoma Health Sciences Center), Marcus L. Quek(Loyola University Medical Center), Mathew Tollefson(WinnMed), Isildinha M. Reis(University of Miami), Badrinath R. Konety(Allina Health), Daniel A. Barocas(Vanderbilt University Medical Center), Gopal N. Gupta(Loyola University Medical Center), Michael Woods(University of Cambridge), Adam S. Kibel(Brigham and Women's Hospital), Raj S. Pruthi(University of North Carolina at Chapel Hill), Nachiketh Soodana‐Prakash(University of Miami), Christopher Weight, Joseph A. Smith(King's College London), Sam S. Chang(Vanderbilt University), David S. Sharp(The Ohio State University), Atreya Dash(University of Washington), Eila C. Skinner(Stanford University), Norm D. Smith(Caris Life Sciences (United States)), Erik P. Castle(WinnMed), Jeffrey S. Montgomery(Ann Arbor Center for Independent Living), Ahmad Shabsigh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
The Lancet
June 1, 2018
Cited by 779


Related Papers